Regen BioPharma Inc. (OTCMKTS:RGBP)
Shares of Regen BioPharma Inc. (OTCMKTS:RGBP) plunged 17.70% in Tuesday’s trading session to end the day at $0.0279 a share. The selloff came on the company reporting progress on the development of small molecules that activate and inhibit NR2F6, a cancer stem cell differentiation.
Regen BioPharma NR2F6 Discovery
Regen BioPharma Inc. (OTCMKTS:RGBP) is a biotechnology firm specializing in the development of regenerative medicine in the stem cell space. The company also develops treatments for Aplastic Anemia and gene silencing therapy for treating various types of cancers. Some of the company’s lead products under development include HemaXellerate for the treatment of damaged bone marrow, and dCellVax a cellular therapy for improving immune system through gene silencing.
A discovery of a new dynamic compound for modulating the NR2F6 checkpoint is the company’s latest achievement on its push to come up with new regenerative treatments. The NR256 program seeks to come up with antagonists of NR2F6 in an effort to trigger the cancer killing potential of patients’ immune system.
Regen BioPharma Inc. (OTCMKTS:RGBP) newly discovered compound that has the potential to treat autoimmune diseases with virtually no toxicity. The company carried out tests on three identified agonists – all of which proved to be reliable in inhibiting cytokine production in stimulated immune cells.
“The Company believes that these recent 3 compound groups just need some fine-tuning to be the basis for our autoimmune therapies. Additionally, using this information, we are now able to ramp up our inhibitor program which focuses on anti-cancer drugs,” said David Koo, Regen BioPharma Inc. (OTCMKTS:RGBP) CEO.
The three compounds were identified from the company’s patented screening methodology and unique chemical libraries. Tests on the structures of the three compounds has resulted in one particular series becoming the favored activator for triggering the autoimmune system.
Regen BioPharma Inc. (OTCMKTS:RGBP) has already carried out tests on over 250 analogues of the favored structure from which it has discovered clear relationships on the structure ability to trigger NR2F6.
Separately, Regen BioPharma Inc. (OTCMKTS:RGBP) did not report any revenues for the first three months of the year. Net loss on the other hand soared to highs of (-$1.39) million compared to a net loss of (-$726,064) reported last year. The company’s net loss for the first six months ended March 31, 2017 soared to $1.96 million compared to $1.42 million for the corresponding period last year.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $RGBP and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.